Capricor Therapeutics Inc (NASDAQ: CAPR) stock suffered a major decline of -11.9% on 1/11/24. The shares closed at $4.60. Moreover, this decline was accompanied by unusually high trading volume at 191% of normal. The stock has declined -11.4% during the last week and has been weak relative to the market over the last nine months.
Current PriceTarget Research Rating
CAPR’s future returns on capital are forecasted to be in line with the cost of capital. Accordingly, the company is expected to continue to be Value Creation neutral.
Capricor Therapeutics has a current Value Trend Rating of F (Lowest Rating). This rating combines highly consistent signals from two proprietary PTR measures of a stock’s attractiveness. Capricor Therapeutics has a very low Power Rating of 13 and a very low Appreciation Score of 1, triggering the Lowest Value Trend Rating.
Rating Review
In light of this highly negative price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment